Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
This study is testing whether adding a medication called bevacizumab to the standard treatment osimertinib works better than osimertinib alone. Doctors want to see if combining these two treatments can control advanced lung cancer for longer and help patients live longer.
You might be able to join if you have advanced non-small cell lung cancer with a specific gene change called an EGFR mutation. The study is for patients who have not previously taken treatments that block blood vessel growth or EGFR-blocking pills, with a few exceptions.
Participants will be randomly chosen to receive either osimertinib alone or combined with bevacizumab. You will also have routine health checks, which include imaging scans like CT, MRI, and heart function tests.
This study is currently recruiting participants at locations including Anchorage, Alaska in the United States.
- 1Compares a two-drug combination against a standard single drug
- 2Focuses on advanced lung cancer with specific EGFR gene changes
- 3Involves regular check-ups, imaging scans, and heart tests
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.